Medical Oncology Service Clinical Core
肿瘤内科服务临床核心
基本信息
- 批准号:10926686
- 负责人:
- 金额:$ 284.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AddressAnnual ReportsCCRCaringClinicClinicalClinical OncologyClinical ResearchClinical ServicesClinical TrialsCommunity Clinical Oncology ProgramCredentialingEducationFeedbackFellowshipGoalsHospitalistsHuman ResourcesImmunotherapyInformation DisseminationInfusion proceduresInternal MedicineLaboratoriesLearningLength of StayLicensingLymphomaMedical OncologyNurse PractitionersNursing ResearchPatientsPhysician AssistantsPoliciesProceduresQuality of CareResearch PersonnelResource SharingRotationScheduleScienceServicesSolid NeoplasmStudentsTrainingVisitWalkingWorkclinical carefallsinpatient servicemeetingsoncology serviceoperationoutpatient programsprogramsvolunteer
项目摘要
Medical Oncology Community: We feel that it is vital to maintain a cohesive medical oncology community for the following reasons. 1. For quality of clinical care. 2. To share resources (patients, research nurses, fellows etc.). 3. To learn from each other. 4. To leverage new collaborative opportunities. 5. To optimize our clinical trials and correlative science. Thus we have liaisons with each branch, program or laboratory (Chief or Clinical Director) with whom we hold regularly scheduled meetings and / or provide service related information for dissemination. This core group also provides feedback on policies and procedures and alerts the MOS when there are issues regarding the efficiency or quality of clinical care or clinical research. The medical oncology service is responsible for maintaining the quality and efficiency of medical oncology care across multiple branches and laboratories that have clinical programs. This includes all medical oncology licensed personnel (Nurse Practitioners, Physician Assistants, Fellows, Volunteers, Staff Clinicians, Investigators and Senior Investigators) as well as internal medicine trained hospitalists who take care of two of the three MOS inpatient services. We have a meeting with the clinic chiefs quarterly to review quality and efficiency of care in the clinic and day hospital (infusion center). We have monthly didactic meetings with the branches involved in the Solid Tumor and Lymphoma Services (WMB, DTB, GMB, TGMB, HAMB, LMB), monthly didactic clinical walk rounds and there are weekly didactic meetings with the medical oncology fellows that all MOS staff are strongly encouraged to attend. The MOS is also involved in all credentialing activities for medical oncology staff. Medical Oncology Clinical Service: We maintain efficient quality care within the in-patient service including around-the-clock scheduling of licensed independent hospitalists and attending level personnel. We also maintain efficient quality care in the outpatient service addressing regulatory, procedural and logistical issues to assure optimal care and optimal clinical research. Medical Oncology Fellowship: While this falls under the Medical Oncology Service, it has a separate annual report. In addition we support an NCI Immunotherapy Fellowship. We also facilitate educational rotations for students, residents and visiting fellows.
医学肿瘤学社区:由于以下原因,我们认为维持具有凝聚力的医学肿瘤学社区至关重要。 1。用于临床护理的质量。 2。共享资源(患者,研究护士,研究员等)。 3。互相学习。 4。利用新的协作机会。 5。优化我们的临床试验和相关科学。因此,我们与每个分支机构,计划或实验室(首席或临床主任)都有联络人,并与我们定期安排的会议和 /或提供与服务相关的信息进行传播。该核心小组还提供有关政策和程序的反馈,并在有关临床护理或临床研究的效率或质量问题时提醒MOS。医学肿瘤学服务负责维持跨多个具有临床计划的分支机构和实验室的医学肿瘤护理的质量和效率。其中包括所有医学肿瘤学许可的人员(护士从业人员,医师助理,研究员,志愿者,临床医生,调查人员和高级研究人员)以及经过内科培训的医院医院医生,他们照顾三个MOS MOS的住院服务中的两名。我们季刊与诊所酋长举行会议,以审查诊所和日医院(输液中心)的护理质量和效率。我们每月与参与实体瘤和淋巴瘤服务的分支机构(WMB,DTB,GMB,TGMB,TGMB,Hamb,LMB)举行教学会议,每月的教学临床步行回合,并且每周与所有MOS员工都强烈鼓励所有MOS的医学肿瘤学会进行每周的教学会议。 MOS还参与了医学肿瘤学人员的所有证书活动。医学肿瘤学临床服务:我们在住院服务中维护有效的质量护理,包括持牌独立住院医生的全天候安排和参加水平的人员。我们还在针对监管,程序和后勤问题的门诊服务中保持有效的质量护理,以确保最佳的护理和最佳的临床研究。医学肿瘤学奖学金:虽然这属于医学肿瘤学服务,但它有一份单独的年度报告。此外,我们支持NCI免疫疗法奖学金。我们还促进了学生,居民和来访者的教育轮换。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Arun Rajan其他文献
Arun Rajan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Arun Rajan', 18)}}的其他基金
Durvalumab in Combination with Olaparib in Non-Small Cell Lung Cancer
Durvalumab 联合奥拉帕尼治疗非小细胞肺癌
- 批准号:
10487055 - 财政年份:
- 资助金额:
$ 284.23万 - 项目类别:
Anti-PD-L1-TGFb antibody (M7824) in advanced non-small cell lung cancer
抗 PD-L1-TGFb 抗体 (M7824) 在晚期非小细胞肺癌中的应用
- 批准号:
10262539 - 财政年份:
- 资助金额:
$ 284.23万 - 项目类别:
Pilot Study of Avelumab in Thymic Epithelial Tumors
Avelumab 在胸腺上皮肿瘤中的初步研究
- 批准号:
10262534 - 财政年份:
- 资助金额:
$ 284.23万 - 项目类别:
CV301 and Anti-PD-1 Therapy in Non-Small Cell Lung Cancer
CV301 和抗 PD-1 治疗非小细胞肺癌
- 批准号:
10702747 - 财政年份:
- 资助金额:
$ 284.23万 - 项目类别:
Anti-PD-L1-TGFb antibody (M7824) in advanced non-small cell lung cancer
抗 PD-L1-TGFb 抗体 (M7824) 在晚期非小细胞肺癌中的应用
- 批准号:
10926393 - 财政年份:
- 资助金额:
$ 284.23万 - 项目类别:
Pilot Study of Avelumab in Thymic Epithelial Tumors
Avelumab 在胸腺上皮肿瘤中的初步研究
- 批准号:
10926388 - 财政年份:
- 资助金额:
$ 284.23万 - 项目类别:
Durvalumab in Combination with Olaparib in Non-Small Cell Lung Cancer
Durvalumab 联合奥拉帕尼治疗非小细胞肺癌
- 批准号:
10702748 - 财政年份:
- 资助金额:
$ 284.23万 - 项目类别:
Phase II Trial of Bintrafusp Alfa in Subjects with Thymoma and Thymic Carcinoma
Bintrafusp Alfa 在胸腺瘤和胸腺癌受试者中的 II 期试验
- 批准号:
10926444 - 财政年份:
- 资助金额:
$ 284.23万 - 项目类别:
Pilot Study of Avelumab in Thymic Epithelial Tumors
Avelumab 在胸腺上皮肿瘤中的初步研究
- 批准号:
10487048 - 财政年份:
- 资助金额:
$ 284.23万 - 项目类别: